Arvinas to Participate in Upcoming Virtual Investor Conferences
March 10 2021 - 3:30PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that it will participate in two
upcoming virtual investor conferences. John Houston, Ph.D.,
President and Chief Executive Officer, will participate in panel
discussions at both conferences.
- Guggenheim Targeted Protein
Degradation Day panel discussion on Tuesday, March 16,
2021 at 10:30 a.m. ET
- 33rd Annual Roth Conference panel discussion
on Wednesday, March 17, 2021 at 5:00 p.m. ET
A live audio webcast of each panel will be available on Arvinas’
website at www.arvinas.com. A replay of each webcast will be
archived on Arvinas’ website for 30 days following the
presentation.
About ArvinasArvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary PROTAC® Discovery Engine platform to engineer
proteolysis targeting chimeras, or PROTAC® targeted protein
degraders, that are designed to harness the body’s own natural
protein disposal system to selectively and efficiently degrade and
remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC® protein degraders against validated
and “undruggable” targets, the company has two clinical-stage
programs: ARV-110 for the treatment of men with metastatic
castrate-resistant prostate cancer; and ARV-471 for the treatment
of patients with locally advanced or metastatic ER+/HER2- breast
cancer. For more information, visit www.arvinas.com.
Contacts for
ArvinasInvestorsWill O’Connor, Stern
Investor Relations ir@arvinas.com
MediaKirsten Owens, Arvinas
Communicationskirsten.owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2024 to May 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From May 2023 to May 2024